VEGFA and hyperlipidemia: Wong et al. [20] reported in a prospective observational study of 35 patients that systemic factors could affect the improvement of anti-VEGF therapy such as HbA1c, serum VEGF levels, lipidemia, renal clearance, and blood pressure.